Ethical Pharmaceuticals Market Research Reports

To order sections of the reports, temas etmek Dr.zadorin Eugene, Doktora

Hepatitis B Drug Market Forecasts by Country

This model contains ten-year commercial forecasts for hepatitis B drug sales by class, molecule and brand for the US, Japonya, Fransa, Almanya, İtalya, İspanya, UK and Turkey.

Reasons to Purchase

Understand the changing market dynamics of hepatitis B drugs, and success factors for leading brands….

$15200.00

HIV Antiretrovirals Market Forecasts

Antihormonal Therapy Market Forecasts

Antihormonal cancer therapies are used predominantly in the treatment of breast and prostate cancers. The high incidence of these tumors translates into a significant commercial potential for drug developers….

$15200.00

Cytotoxic Therapies: Drug Launches in Rare Indications to Offset Sales Decline

Growth of cytotoxics will remain static over the forecast period with a CAGR of -0.1%….

$15200.00

Antihormonal Cancer Therapies: Leading Brands Strive to Minimize Generic Sales Erosion

Antihormonal cancer therapies are used predominantly in the treatment of breast and prostate cancers. The high incidence of these tumors translates into a significant commercial potential for drug developers….

$15200.00

Gastric Cancer

Despite advances in surgery and the use of multimodality therapy, survival outcomes remain poor for gastric cancer patients. There is an urgent need for more effective therapies to improve survival rates in patients presenting with both localized and advanced disease….

$15200.00

Spondyloarthropathies: Disease Perception Limits Market

Psoriatic arthritis and ankylosing spondylitis form part of the group of diseases known as the spondyloarthropathies. Psoriatic arthritis is a form of inflammatory arthritis associated with psoriasis, whilst ankylosing spondylitis causes arthritis of the spine and sacroiliac joints….

$15200.00

Commercial Insight: Kardiyovasküler ve Metabolik Pazara Genel Bakış

Yenilikçi Geliştirme Hattı Sınırlı Büyüme Sağlıyor

Birinci Basamak Sağlık Piyasaları Jenerik Hale Geldikçe

giriiş

Datamonitor, antidiyabetik tedavilerin kardiyovasküler ve metabolik pazarlarda en büyük gelir getiren ilaç olarak ortaya çıkmasını bekliyor. 2018. Geniş ve çeşitli bir geliştirme hattı, gişe rekorları kıran bir dizi yeni ilaç sağlayacaktır, ancak hipertansiyon ve dislipidemi birinci basamak sağlık hizmetleri pazarlarının yoğun şekilde jenerikleştirilmesi, genel pazarın yalnızca %0 oranında büyümesine yol açacaktır.….

$15200.00

İlaç Lisanslamasına Genel Bakış: Dışsallaştırma Yoğunlaştıkça Riskten Kaçınma Yaratıcılığı Besler

Big Pharma dahili R'sini yeniden yapılandırmaya devam ediyor&Yaklaşan krizin etkilerini azaltmaya yardımcı olmak için yaygın maliyet düşürücü önlemlerin bir parçası olarak D departmanları 2011 patent uçurumu. Boru hattındaki boşlukları yeni ürünlerle doldurmak, companies continue to make acquisitions and form partnerships with small pharma, biotech companies and academia, although the relationships between each are becoming increasingly dynamic….

$15200.00

The 2011 Top Ten World’s Leading Pharmaceutical Companies

A thought-provoking report on performance, capabilities, goals and strategies of the major competitors in the worldwide pharmaceutical market. The report is designed to provide the pharmaceutical industry executives with strategically significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs….

$13200.00

Product Profiles: Prostate Cancer – Recent approvals create competitive environment for new market entrants

giriiş

Androgen deprivation therapies (ADTs) are the main treatment type for hormone-sensitive prostate cancer. Hastalık hormonal olarak beslendiğinden, Kimyasal hadım etme, birkaç yıl boyunca yeterli hastalık kontrolü sağlar….

$11400.00

Asya Pasifik İlaç Pazarı: Lider Tedarikçilerin Stratejik Değerlendirmeleri

Bu rapor, endüstri yöneticilerine stratejik açıdan önemli rakip bilgileri ve Asya Pasifik ilaç pazarındaki lider oyuncuların analizini sağlar..

Rapor, ilaç pazarına dünya çapında stratejik bir genel bakış sunuyor, içermek:

$9800.00

Avrupa İlaç Pazarı: Lider Tedarikçilerin Stratejik Değerlendirmeleri

Bu rapor, endüstri yöneticilerine stratejik açıdan önemli rakip bilgileri ve Avrupa ilaç pazarındaki lider oyuncuların analizini sağlar..

Rapor, ilaç pazarına dünya çapında stratejik bir genel bakış sunuyor, içermek:

$9800.00

Kuzey Amerika İlaç Pazarı: Lider Tedarikçilerin Stratejik Değerlendirmeleri

This report provides industry executives with strategically significant competitor information and analysis of the leading players in the North American pharmaceutical market.

Rapor, ilaç pazarına dünya çapında stratejik bir genel bakış sunuyor, içermek:

$9800.00

Global Cardiovascular Drug Market: Lider Tedarikçilerin Stratejik Değerlendirmeleri

This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global Cardiovascular Drug Market.

Rapor, ilaç pazarına dünya çapında stratejik bir genel bakış sunuyor, içermek:

$9800.00

Global CNS Drug Market: Lider Tedarikçilerin Stratejik Değerlendirmeleri

This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global CNS Drug Market.

Rapor, ilaç pazarına dünya çapında stratejik bir genel bakış sunuyor, içermek:

$9800.00

Global Infectious Disease Drug Market: Lider Tedarikçilerin Stratejik Değerlendirmeleri

This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global Infectious Disease Drug Market.

Rapor, ilaç pazarına dünya çapında stratejik bir genel bakış sunuyor, içermek:

$9800.00

Global Oncology Drug Market: Lider Tedarikçilerin Stratejik Değerlendirmeleri

This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global Oncology Drug Market.

Rapor, ilaç pazarına dünya çapında stratejik bir genel bakış sunuyor, içermek:

$9800.00

Pharmaceutical M&A in Asia-Pacific: India and China Drive Regional Activity, but Japan Dominates High Value Transactions

Expanding healthcare coverage in emerging Asia-Pacific markets, rapid economic growth and burgeoning middle classes are attracting foreign M&A as companies attempt to offset future losses from the looming threat of the 2011 “patent uçurumu” and slowing growth in major developed markets. As these markets expand, consolidation of the domestic industry is also driving M&A in the Asia-Pacific region….

$7600.00

Mapping the Healthcare Landscape – Bringing Pharmaceuticals into Focus

giriiş

Courtesy of the patent cliff, the pharmaceutical industry is set for a dramatic slow down in revenue growth from 2011. Industry players are therefore looking to implement strategies which will cushion them against the anticipated revenue short-fall, with diversification away from pharmaceuticals into other healthcare sectors one avenue under consideration.

$7600.00

Rx-to-OTC Strategies: Maximizing Commercial Potential

With the growing cost of developing novel drugs, combined with the declining trend in the number of drugs gaining regulatory approval, the use of lifecycle management is playing a more important role in the increasingly cost-conscious pharma industry. Rx-to-OTC switching strategy is being increasingly employed to either enhance existing franchise revenues or protect branded revenues from generic competition….

$5700.00

İnflamatuar Bağırsak Hastalığı: Incidence Prevalence, Erken Teşhis ve İyileştirilmiş Hayatta Kalma

Giriş 1950'lerden Bu Yana, İnflamatuar barsak hastalığının görülme sıklığı dünya çapında önemli ölçüde arttı. Fakat, son yirmi yılda, İBH insidansının Batı'da istikrar kazanmaya başlaması, insidansın zirveye ulaştığını düşündürmektedir….

$5700.00

İnsan Genom Bilimleri

giriiş

Bu analiz, reçeteli ilaç sektöründe İnsan Genomu Bilimleri'nin geçmiş ve tahmin performansını inceliyor. Profil, önemli ürün analizlerini ve tahminlerini kapsar, boru hattı değerlendirmesi, 6 yıllık dönem boyunca şirket stratejisinin ve finansal performansının değerlendirilmesi ve değerlendirilmesi.

$5700.00

Amgen

giriiş

Bu analiz Amgen'in reçeteli ilaç sektöründeki geçmiş ve tahmin performansını inceliyor. Profil küresel şirket stratejisini kapsıyor, portföy ve boru hattı analizi ve finansal performansın değerlendirilmesi, ile 1-6 year sales forecasts for key drugs.

$5700.00

Johnson & Johnson

giriiş

This analysis examines the historical and forecast performance for Johnson & Johnson in the prescription pharmaceutical sector. Profil küresel şirket stratejisini kapsıyor, portföy ve boru hattı analizi ve finansal performansın değerlendirilmesi, ile 1-6 year sales forecasts for key drugs.

$5700.00

Established and Emerging Biotech Clusters

giriiş

There has been widespread interest in establishing geographically focused clusters of biotechnology companies and related organizations. It is important for all stakeholders to understand the capabilities of different clusters across the world….

$4795.00

Back to the Lab! Improving R and D Productivity and Efficiency with LIMS and ELNs

giriiş

The rigorous R&D processes of pharma and biotech have provided them with a wealth of data, documents and knowledge, but this information is often held in organizational silos, paper laboratory notebooks and disparate IT systems, rendering them virtually useless. Öyleyse, yaşam bilimleri şirketleri siloları kaldırmak ve R'yi birbirine bağlamak için LIMS ve ELN'leri uyguluyor&Kuruluş çapındaki D grupları….

$3995.00

Farmasötik İşgücünü ve Saha Azaltmalarını Yönetme Stratejileri: Hukuk Analizi, Verimlilik, ve Kalite Kontrol Sorunları

İçinde 2007, yaklaşan patent uçurumu ve bunun sonucunda ortaya çıkan maliyetleri düşürme ihtiyacı nedeniyle, Büyük ilaç sektörü ilk kez kimyasal API üretimini Çin ve Hindistan'a dış kaynak olarak sağlamaya başladı. Bundan önce, İki ülkede yalnızca jenerik ilaç firmaları üretim yapıyordu….

$3835.00

İmmünosupresanlar, Organ Nakli, ve Rejeneratif Tıp Potansiyeli: Pazar Büyüklüğü, Rekabetçi Ortam, ve Boru Hattı Analizi

Bu rapor son on yılda geliştirilen tedavi protokollerini incelemektedir.. Aynı zamanda geliştirilmekte olan yeni bileşikleri de değerlendirir., highlighting potential clinical advances along with analysis of the potential impact of regenerative medicine (kök hücreler) on the market, with drivers and resistors to market growth….

$3835.00

Cancer Market Outlook to 2015: Rekabetçi Ortam, Pazar Büyüklüğü, Pipeline Analysis, and Growth Opportunities

The report provides epidemiological analysis, and forecasts prevalence of the major cancer indications turning 2009-2015, including lung, göğüs, colorectal, and ovarian cancer markets. Also included are detailed analyses of the clinically differentiated products in the cancer pipeline by indication, and sales forecasts for key R&D pipeline products in the global cancer market….

$3835.00

Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion

GPCRs are being actively pursued as a target class for developing new therapeutics for various indications. This report discusses the developments in targeting selected, recently deorphaned GPCRs….

$3835.00

OTC Opportunities in Europe, US and Japan: Key Trends, Leading Players and Future Rx-OTC Switching

The developed OTC markets in US and UK, are heavily reliant on the prescription (Rx)-to-OTC switching of new-generation products as a means of generating growth. Switching also plays an important role for less-developed markets, such as France, İspanya, Italy and Japan, although these countries are currently playing ‘catch-up’ with their developed peers….

$3835.00

Opportunities in Non-Surgical Bio-Implants: Injectable Biomaterials, Uygulamalar, and Leading Players

The report details the major players, market opportunities, and emerging sectors that are changing the landscape of injectable treatments and major applications in cosmetic dermatology and orthopedics. It provides insights into potential high-growth prospects for novel subcutaneous, intradermal, and intra-articular products, as well as novel matrix formulations for tissue and bone regeneration….

$3835.00

Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates

This report explores over 70 new proprietary technologies, licensing deals, and intellectual property positions.

Kapsam

Challenges and benefits of therapeutic vaccination….

$3835.00

Advances in Imaging Biomarkers: Innovative Technologies, Applications in R&D and Clinical Practice, Informatics and Regulatory Requirements

This report discusses advances in key technologies, the use of imaging biomarkers in drug discovery, as well as development and current use in clinical practice. It also outlines key collaborative initiatives in standardizing imaging technologies and informatics, as well as improving quantification and qualification without which the vision will not be realized….

$3835.00

Preclinical Development of Monoclonal Antibodies and Related Biologicals: Emerging Technologies and New Therapeutic Candidates

This report examines leading pharmaceutical companies involvement in developing monoclonal antibody-based drugs internally and the recent M&A activity. Bundan fazla 80 current and emerging technologies are analyzed….

$3835.00

Future of Biologicals: Market Overview, Innovations and Company Profiles

This report analyzes the strengths and limitations of the biopharma marketplace, important research avenues being pursued, and an overview of recent R&D developments.

This report also provides assessment of the contribution of biopharma to the management of major diseases, identifies possible avenues for new product development, and examines national and regional markets in terms of comparative importance and developing opportunities….

$3835.00

Innovations in Injectables: Current and Emerging Technologies to Improve Drug Delivery

This report evaluates the current and evolving technologies used for injectable drug delivery, key therapeutic areas, as well as barriers and driving forces. Leading and emerging companies are analyzed according to the technology type, and new product pipeline….

$3835.00

Cardiovascular Market Outlook to 2015

This report provides comprehensive coverage of the cardiovascular market, including disease overview and detailed epidemiological analyses of the major indications. The report contains a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecasts, and competitive landscape for the major players….

$3835.00

İlaç Üretiminde Enzimler

giriiş

Bu rapor, farmasötik üretiminde enzimatik adımların uygulanmasının yararlarını ve zorluklarını incelemektedir.. Enzimlerin neden yeşil kimya ve endüstriyel biyoteknolojinin merkezinde yer aldığını kapsar.….

$3835.00

Hepatit Piyasasının Görünümü 2016

giriiş

Bu rapor hepatit pazarının kapsamlı kapsamını sunmaktadır, ayrıntılı bir epidemiyolojik analiz içeren. Rapor mevcut lider markaları analiz ediyor, ve hetpatit pazarındaki önde gelen oyuncuların profilleri….

$3835.00

Latin Amerika'da aşılar: Brezilya'daki Fırsatlar, Meksika ve Arjantin

Geçtiğimiz on yılda, aşılar eczacılık için cazip bir ticari teklif olarak yeniden ortaya çıktı. Gelişmiş dünya, daha iyi sağlık altyapısı ve daha yüksek fiyat seviyeleri nedeniyle aşı üreticilerinin ilk odak noktası oldu….

$3800.00

İlaç Endüstrisi Altyapısına Genel Bakış

giriiş

Pharma companies face a number of resistors to profit growth including the looming patent cliff causing a significant slowing in branded sales, coupled with ongoing R&D challenges. Pharma companies are therefore taking by boosting performance through enhancing operating profit through a combination of operating margin and sales growth.

$3800.00

Healthcare System and Drug Regulatory Overview

giriiş

Healthcare expenditure is growing fast in all markets, driven by aging populations, a growing prevalence of chronic diseases, expanding government healthcare coverage, use of expensive drugs. Ayrıca, as a result of the economic downturn, healthcare funding is under increased scrutiny by governments in developed markets looking to pay down their debts.

$3800.00

Biosimilar Market Overview

Introduction Biosimilars were estimated to have generated approximately $200m in sales during the twelve months to March 2010. Going forward, with branded biologics worth $55bn set to face patent expiry between 2011 Ve 2015, this presents a major opportunity for companies looking to enter the biosimilars market.

$3800.00

HCV – New Market Entrants are Changing Corporate Landscape

giriiş

The recent FDA approval of Vertex’s Incivek/Incivo (telaprevir) and Merck’s Victrelis (boceprevir) has heralded a new era in the treatment of hepatitis C (HCV). These agents are also changing the HCV corporate landscape by paving the way for companies that traditionally do not have a presence in HCV to develop the next generation small molecule antivirals.

$3800.00

HIV in Emerging Markets (Brezilya, Rusya, Hindistan): Growing Need for Second and Third Line Therapies

giriiş

Faced with limited growth opportunities in western markets, HIV drug developers are looking to expand into emerging markets, marked by a higher disease burden and greater medical unmet need. Efforts to improve treatment coverage coupled with a growing affluent middle class and private sector have turned countries like Brazil, Russia or India into a promising commercial opportunity.

$3800.00

Generics Market Overview

giriiş

The combined generics market size is valued at approximately $77bn in the US, Japonya, the five major EU markets (Fransa, Almanya, İtalya, İspanya, and the UK), the BRIC markets (Brezilya, Rusya, Hindistan, and China), and Australia combined. With branded pharma set to lose approximately $100bn in sales due to the patent cliff, this presents a significant opportunity for generics players during 2011–15.

$3800.00

AstraZeneca: Performans, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

AstraZeneca'nın stratejik değerlendirmesi, dünyanın önde gelen ilaç şirketlerinden biri, önemli rakip bilgileri sağlar, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. Rapor, şirketin performansının kapsamlı bir analizini sunuyor, capabilities, küresel ilaç pazarındaki hedefler ve stratejiler.

İçerir 97 sayfalar ve 8 tablolar

$1900.00

Bristol-Myers Squibb: Performans, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

Bristol-Myers Squibb'in stratejik değerlendirmesi, dünyanın önde gelen ilaç şirketlerinden biri, önemli rakip bilgileri sağlar, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. Rapor, şirketin performansının kapsamlı bir analizini sunuyor, capabilities, küresel ilaç pazarındaki hedefler ve stratejiler.

İçerir 88 sayfalar ve 20 tablolar

$1900.00

GlaxoSmithKline: Performans, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

GlaxoSmithKline'ın stratejik değerlendirmesi, dünyanın önde gelen ilaç şirketlerinden biri, önemli rakip bilgileri sağlar, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. Rapor, şirketin performansının kapsamlı bir analizini sunuyor, capabilities, küresel ilaç pazarındaki hedefler ve stratejiler.

İçerir 149 sayfalar ve 13 tablolar

$1900.00

Johnson & Johnson: Performans, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

Johnson'ın stratejik değerlendirmesi & Johnson, dünyanın önde gelen ilaç şirketlerinden biri, önemli rakip bilgileri sağlar, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. Rapor, şirketin performansının kapsamlı bir analizini sunuyor, capabilities, küresel ilaç pazarındaki hedefler ve stratejiler.

İçerir 103 sayfalar ve 8 tablolar

$1900.00

Merck: Performans, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

Merck'in stratejik değerlendirmesi, dünyanın önde gelen ilaç şirketlerinden biri, önemli rakip bilgileri sağlar, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. Rapor, şirketin performansının kapsamlı bir analizini sunuyor, capabilities, küresel ilaç pazarındaki hedefler ve stratejiler.

İçerir 99 sayfalar ve 8 tablolar

$1900.00

Novartis'in: Performans, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

Novartis'in stratejik değerlendirmesi, dünyanın önde gelen ilaç şirketlerinden biri, önemli rakip bilgileri sağlar, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. Rapor, şirketin performansının kapsamlı bir analizini sunuyor, capabilities, küresel ilaç pazarındaki hedefler ve stratejiler.

İçerir 140 sayfalar ve 11 tablolar

$1900.00

Pfizer: Performans, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

Pfizer'in stratejik değerlendirmesi, dünyanın önde gelen ilaç şirketlerinden biri, önemli rakip bilgileri sağlar, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. Rapor, şirketin performansının kapsamlı bir analizini sunuyor, capabilities, küresel ilaç pazarındaki hedefler ve stratejiler.

İçerir 117 sayfalar ve 7 tablolar

$1900.00

Roche: Performans, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

Roche'un stratejik değerlendirmesi, dünyanın önde gelen ilaç şirketlerinden biri, önemli rakip bilgileri sağlar, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. Rapor, şirketin performansının kapsamlı bir analizini sunuyor, capabilities, küresel ilaç pazarındaki hedefler ve stratejiler.

İçerir 112 sayfalar ve 11 tablolar

$1900.00

Sanofi-Aventis: Performans, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

Sanofi-Aventis'in stratejik değerlendirmesi, dünyanın önde gelen ilaç şirketlerinden biri, önemli rakip bilgileri sağlar, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. Rapor, şirketin performansının kapsamlı bir analizini sunuyor, capabilities, küresel ilaç pazarındaki hedefler ve stratejiler.

İçerir 97 sayfalar ve 8 tablolar

$1900.00

Wyeth: Performans, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

Wyeth'in stratejik değerlendirmesi, dünyanın önde gelen ilaç şirketlerinden biri, önemli rakip bilgileri sağlar, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. Rapor, şirketin performansının kapsamlı bir analizini sunuyor, capabilities, küresel ilaç pazarındaki hedefler ve stratejiler.

İçerir 65 sayfalar ve 7 tablolar

$1900.00

Eli Lilly: Performans, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

Eli Lilly'nin stratejik değerlendirmesi, dünyanın önde gelen ilaç şirketlerinden biri, önemli rakip bilgileri sağlar, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. Rapor, şirketin performansının kapsamlı bir analizini sunuyor, capabilities, küresel ilaç pazarındaki hedefler ve stratejiler İçerir 65 sayfalar ve 7 tablolar.

$1900.00

Abbott: Performans, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

Abbott'un stratejik değerlendirmesi, dünyanın önde gelen ilaç şirketlerinden biri, önemli rakip bilgileri sağlar, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. Rapor, şirketin performansının kapsamlı bir analizini sunuyor, capabilities, küresel ilaç pazarındaki hedefler ve stratejiler.

İçerir 90 sayfalar ve 8 tablolar

$1900.00

Farmasötik Temel Trendler: Sosyo-Demografik ve Ekonomik Genel Bakış

giriiş

Yaşlanan nüfus, the growing prevalence of chronic disease, greater use of expensive treatments, and expanding public healthcare coverage in markets such as the US are stretching existing healthcare resources. Healthcare payers are also feeling the impact of the global economic downturn through reduced funding via taxation as a result of rising unemployment.

$1900.00

Prescription Pharmaceutical Sales Overview

giriiş

Pharma is set to loose approximately $108 billion in sales due to the patent cliff and resultant generic erosion of branded sales during 2010–15, while the industry is also feeling the affect of the recent global economic downturn. In response, the industry is implementing a number of strategies to drive sales and profitability going forward: product innovation, diversification and cost-containment.

$1900.00

Key Pharmaceutical Industry Strategic Trends

giriiş

A number of factors have and will continue to impact pharmaceutical sales and profits going forward. As a result of rising healthcare costs, healthcare budgets are being stretched….

$1900.00

The 2011 Global Pharmaceutical Market Dynamics and Trends Through 2016

A 25-page worldwide strategic overview of the pharmaceutical market, içermek:

Sales forecast for major product segments: etik, OTC, jenerikler.

Sales forecast for key geographic regions: North America, Avrupa, Japonya, Latin Amerika….

$1850.00

The 2011 Leading Pharmaceutical Companies Strategic Directions

For each company, the report provides insightful strategic assessments, içermek:

Major strengths and weaknesses.

İşletme, new product development, and marketing objectives and strategies….

$1850.00

The 2011 Leading Pharmaceutical Companies Financial Analyses

Each company’s analysis provides:

BİZ….

$1850.00

The 2011 Leading Pharmaceutical Companies R&D Expenditures and Major Programs

For each company, the report provides:

Annual R&D budget.

Research facilities and staff….

$1850.00

The 2011 Leading Pharmaceutical Companies Collaborative Arrangements

For each company, the report analyzes:

Major joint venture, dağıtım, OEM, and licensing partners, both industrial and academic.

Terms of collaborative agreements and specific products involved.

The companies analyzed in the report:

$1850.00

The 2011 Leading Pharmaceutical Companies Business Organizations and Senior Management Profiles

For each company, the report provides:

History of the company’s pharmaceutical business evolution, which is important to understanding the corporate culture, management mentality, and strategies.

Most recent M&A activity and significant organizational changes….

$1850.00

Leading Pharmaceutical Companies Technological Know-How

For each company, the report analyzes:

Internally developed and acquired technologies, süreçler, and related capabilities.

Know-how in biotechnology and other pertinent fields….

$1850.00

The 2011 Leading Pharmaceutical Companies Product Portfolio Analyses

For each company, the analyses present:

Extensive review of major ethical, OTC, and generic drugs.

Most recent new drug introductions and indications.

$1850.00

Leading Pharmaceutical Companies Marketing Tactics

For each company, the analysis presents:

Sales force in the U.S….

$1850.00

The 2011 Leading Pharmaceutical Companies Comparative Analysis

This report ranks the world’s major pharmaceutical companies according to the following criteria:

Sales and market shares.

Operating profit and margins….

$850.00

To order sections of the reports, temas etmek Dr.zadorin Eugene, Doktora